Comparison of Effect of Oxytocin and Prostaglandin E1 on Cervix Prior to Curettage in First Trimester

Document Type : Original Article


1 Assistant Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

3 Resident of Obstetrics and Gynecology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.


Introduction: In missed abortion, expulsion of the conceptus does not occur despite a prolonged period after embryonic death. Coagulation defects due to retention of a dead fetus are rare, however expectant management, can cause anxiety and many women prefer to have the uterus evacuated. For decreased complication and simplicity of curettage, it is better to ripening the cervix. This study designed to compare the efficacy of oxytocin and misoprostol for cervical ripening in first trimester in patient with missed abortion.
Methods: In this clinical application study, 126 patients participated who admitted for evacuation of missed abortion in Imam Khomeini and Razi hospitals in Ahvaz, Iran 2006-2007. Patients were randomly assigned to two groups having 63 patients in each group. Primary dilatation of cervix measured with dilator .One group (group I) was given intravenous infusion of 50U oxytocin in 1000cc ringer in 8 hour from 12 midnight until 8 Am, at a rate of 40 drops in minute. Another group (group II) was given 200µg intravaginal misoprostol at 12 midnight. Dilatation of cervix measured before curettage between two groups and then compared. Data statistically analyzed by using SPSS software version 11, t-test and paired t-test. P value less than 0.05 was considered statistically significant.
Results: Mean age of patient was 27±6.08 in range of 15-47 years. The mean of dilatation in group I was 2.5 mm (49%) and group II was 4 mm (76%) and two groups had significant difference (p<0.001). In patients who receive oxytocin, there is no significant difference in cervical dilatation between nulliparous and multiparous, but in patients who receive misoprostol, the cervical dilatation had significant difference between these two groups (p<0/001).
Conclusion: Oxytocin and misoprostol are effective for ripening of cervix before curettage, but misoprostol is more effective than oxytocin.


1. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap III L, Wenstrom KD.Williams obstetrics. 22nd ed.
New York:McGraw-Hill;2004:240-1.
2. Grimes DA. Management of abortion. In: Rock JA, Jones III HW. Te Linde’s operative gfynecology. 9th ed.
Philadelphia:Lippincott Williams & Wilkins;2003.483-505.
3. Eschenbach DA. Pelvic infections and sexually transmitted diseases. In: Scott JR, Gibbs RS, Karlan BY, .Haney
AF. Danforth’s obstetrics & gyneocology. 9th ed. Philadelphia:Lippincott Williams & Wilkins;2004:581-603.
4. David M Chen FC. Comparsion of isosorbide mononitrate (Mono Mack) and misoprostol )Cytotec) for cervical
ripening in the first trimester missed abortion. Arch Gynecol Obstet 2005 Dec;273(3):144-5.
5. Allen RH, Goldberg AB; Board of Society of Family Planning. Cervical dilation before first-trimester surgical
abortion (<14 week’s gestation).SFP Guideline 2007I. Contraception 2007 Aug;79(2):139-56.
6. Cakir L, Dilbaz B, Caliskan E, Dede FS, Dilbaz S, Haberal A. Comparsion of oral and vaginal misprostol for
cervical ripening before manual vaccum aspiration of first trimester preganancy under local anesthesia: a
randomized placebo-controlled study. Contraception 2005 May;71(5):337-42.
7. Meckstroth KR, Darney PD. Prostaglandins for first-trimester termination. Best Pract Res Clin Obstet Gynaecol
2003 Oct;17(5):745-63. Review.
8. Herabutya Y, O-Prasertsawaf P. Misoprostol in the management of missed abortion. Int J Gynaecol Obstet
1997 Mar;56(3):263-6.
9. Hernandez-Valencia M. Cervical ripening with prostaglandin EL: how an ambulatory method decreases the
hospital stay in abortus with intrauterine fetal demise. Fetal Diagn Ther 2003 Jan-Feb;18(1):54-8.
10. Khan RU, El-Refaey H, Sharma S, Sooranna D, Stafford M. Oral, rectal, and vaginal pharmacokinetics of
misoprostol. Obstet Gynecol 2004 May;103(5 Pt 1):866-70.
11. Vineeta M, Sushil K. Vaginal misoprostal for first trimester pregnancy termination. Obstet Gynecol India 2005
12. Cook RJ, Dickens BM, Horga M. Safe abortion: WHO technical and policy guidance. Int J Gynaecol Obstet
2004 Jul;86(1):79-84.
13. Maclsaac L, Grossman D, Balistrei E, Darney P. A randomized controlled trial of laminaria, oral misprostol, and
vaginal misprostol before abortion. Obstet Gynecol 1999 May;93(5 Pt 1)+:766-70.